[REVISION HISTORY]
ctDNA blood test developments in cancer monitoring
3 recorded revisions of this situation.
What changed
2026-10-30 01:37 UTC → 2026-11-07 06:50 UTC ·
added
removed
Recent research highlights the growing utility of circulating tumor DNA (ctDNA) blood tests as biomarkers for monitoring various cancers. In lung cancer management, findings from the NeoCOAST-2 trial suggest that measuring ctDNA can help predict treatment outcomes for patients with operable non-small cell lung cancer. Specifically, Analysis presented at the ESMO Congress 2026 indicates that patients whose ctDNA becomes undetectable during therapy therapy, such as those receiving combinations of immunotherapy with chemotherapy or agents like oleclumab, monalizumab, or datopotamab deruxtecan, are more likely to remain free of cancer-related events, allowing events. This tumor-agnostic approach allows clinicians to assess treatment response before surgery. Similarly, studies surgery, rather than waiting for post-surgical pathological results. Further research published in The Journal of Molecular Diagnostics suggests that combining liquid biopsies with computed tomography (CT) scans may improve detection. Integrating ctDNA data with imaging into computer models could help identify minimal residual disease months before it is visible on traditional imaging, potentially helping doctors decide on additional treatments or helping patients avoid unnecessary interventions. In breast cancer cancer, studies indicate that tissue-free epigenomic assays can provide high prognostic value for detecting recurrence in early-stage patients. This method has shown patients, showing a sensitivity of 73% within one year and a specificity of 99.6%, potentially identifying asymptomatic metastases before they appear on medical imaging. Furthermore, monitoring year. Monitoring ctDNA can also identify mutations like those in the ESR1 gene, which signal resistance to endocrine therapy and may allow for proactive treatment adjustments. therapy. The SERENA-6 study indicates that monitoring ctDNA can identify these genetic mutations associated with endocrine therapy resistance before they become visible on imaging, which may reduce the risk of disease progression.
Versions
- 2026-11-07 06:50 UTC ctDNA blood test developments in cancer monitoring
- 2026-10-30 01:37 UTC ctDNA blood test developments in cancer monitoring
- 2026-10-29 04:55 UTC ctDNA blood test developments in cancer monitoring
- 2026-10-28 16:15 UTC ctDNA blood test developments in cancer monitoring
Select a version to see what changed compared to the one before it.